Award Number: DOD Award W81XWH-08-2-0068

TITLE: A Randomized Controlled Trial of Medical Therapies for Chronic Post-Traumatic Headaches

PRINCIPAL INVESTIGATOR: Jay Erickson, MD, PhD, LTC US Army

CONTRACTING ORGANIZATION: Henry M. Jackson Foundation
Rockville, MD 20852

REPORT DATE: May 2010

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: (Check one)

X Approved for public release; distribution unlimited
□ Distribution limited to U.S. Government agencies only; report contains proprietary information

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
A randomized, placebo-controlled clinical trial is being conducted to evaluate the effectiveness of propranolol, topiramate, and amitriptyline as treatments for chronic post-traumatic headaches secondary to combat-related mild head injury. The study is in the first of three years. 34 of 240 subjects have been enrolled. The study medications are well tolerated. Study subjects had a 60% decrease in headache frequency after 3 months of treatment. There is insufficient data at this time to draw conclusions about the efficacy of specific study medications. The study remains open to enrollment.
Introduction
Headaches are the most common symptom after mild traumatic brain injury (1-4). Chronic post-traumatic headaches (PTHAs) develop in 20% of TBI victims, contributing to disability, healthcare utilization, and poor quality of life (5-6). There are no prospective, controlled clinical trials evaluating medical treatments for chronic post-traumatic headaches (7). The purpose of this study is to determine the effectiveness of propranolol, amitriptyline, and topiramate as treatments for chronic PTHAs. We are conducting a single-center, prospective, randomized, double-blind, placebo-controlled, multi-arm trial to evaluate propranolol, amitriptyline, and topiramate for treatment of chronic PTHAs. A total of 240 patients meeting International Classification of Headache Disorders (ICHD) diagnostic criteria for chronic post-traumatic headaches will be enrolled. Subjects are recruited from the Traumatic Brain Injury Program and the Neurology Clinic at Madigan Army Medical Center, Ft. Lewis, WA. Study participants are U.S. Army soldiers with chronic post-traumatic headaches attributable to mild traumatic head injury sustained while deployed to a combat theater. Participants are randomized to receive placebo, propranolol 80 mg daily dose, amitriptyline 50 mg daily dose, or topiramate 100 mg daily dose for 3 months. The primary outcome measure is the number of moderate-severe headache days during the third month of treatment. Secondary outcome measures include the proportion of subjects with at least a 50% reduction in headache frequency, headache-related disability as measured by the Headache Impact Test and Migraine Disability Assessment Scale, PTSD symptom checklist score, and medication side effects. The findings of this study will improve the care of patients with chronic headaches after traumatic brain injury.

Body:
As of May 1, 2010, 282 patients have been screened for study enrollment and 46 patients have been enrolled. In the last year, 10 patients were enrolled. Study outcome measures have been obtained on 33 subjects. 13 patients disenrolled prior to study outcomes being obtained. The most common reason for a subject disenrolling was that he moved away from the geographic region.

Interval analysis of blinded data in 33 subjects showed that headache frequency decreased from a mean of 10.9 days per month during the baseline month to 6.3 days per month during the third
month of treatment (see graph). This is a 42% decline in headache frequency. These data are consistent with our hypothesis and suggest that one or more of the study treatments may be having a beneficial effect on headaches. There are too few subjects in each treatment arm to compare the outcomes of different treatments at this time.

The study medications have been well tolerated. One patient temporarily discontinued study medication after experiencing mild sedation, but was able to re-start medication and complete study participation. No serious adverse events have occurred.

The study remains open to enrollment. Enrollment was slow over the last year because most combat troops at Ft. Lewis were deployed. The enrollment rate is expected to increase sharply starting in June 2010 when three brigade of troops return to Ft. Lewis. Our goal is to enroll 12 patient per month for the next 12 months. The duration of the study will likely need to be extended to complete enrollment.

**Key Research Accomplishments:**
1. The study protocol was approved by the IRB in 2008.
2. A research P.A. was hired and trained in 2008-09.
3. The investigational pharmacy procured identical-appearing study medications and placebo capsules, and developed a system for randomizing, labeling, dispensing, and monitoring study pills.
4. The study has enrolled 46 of 240 subjects.
5. A study database has been generated.
6. The study continues to enroll new subjects.
7. Interval analysis of blinded data shows overall improvement of headaches, good tolerability of study medications, and no serious adverse events.

**Reportable Outcomes:**
There are no reportable outcomes at this time.
Conclusion:
This clinical trial is evaluating the effectiveness of three prophylactic medications for chronic post-traumatic headaches. The study is now 19% complete with 46 out of 240 subjects enrolled. There is insufficient data at this time to draw meaningful conclusions about the efficacy of specific study medications. However, interval data analysis has shown an overall 42% improvement in headache frequency among study participants. The study medications have been well tolerated without any serious adverse events. Study enrollment is expected to increase sharply throughout the next year when over 15,000 troops return to Ft. Lewis. The study may need to be extended beyond past May 2011 in order to enroll all 240 subjects.

References:
Supporting Data:

Figure 1. Monthly frequency of moderate-severe headaches among the first 33 subjects with available outcome data.

Appendices: none